Sicart Associates’s CG Oncology CGON Stock Holding History

Sicart Associates’s Portfolio CGON Stock Details CGON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.69M	Hold	25,000	–	–	0.43%	42
2025 Q4	$1.04M	Hold	25,000	–	–	0.28%	45
2025 Q3	$1.01M	Hold	25,000	–	–	0.27%	45
2025 Q2	$650K	Hold	25,000	–	–	0.23%	45
2025 Q1	$612K	Hold	25,000	–	–	0.21%	46
2024 Q4	$717K	Hold	25,000	–	–	0.26%	46
2024 Q3	$943K	Hold	25,000	–	–	0.33%	45
2024 Q2	$789K	Hold	25,000	–	–	0.3%	46
2024 Q1	$1.1M	Buy	+25,000	New	+$1.02M	0.4%	46

Other funds holding CGON

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sicart Associates's CGON Position: Q1 2026 in Review

Sicart Associates held its CG Oncology (CGON) position steady in Q1 2026 at 25,000 shares worth $1.69M. The position accounts for 0.43% of the portfolio, ranked #42.

Sicart Associates first reported a position in CGON in Q1 2024 and has held it in 9 quarters since. 233 funds tracked by Wall St. Rank hold CGON as of Q1 2026.

Sicart Associates held 25,000 shares of CG Oncology worth $1.69M as of Q1 2026.
Sicart Associates left its CG Oncology share count unchanged in Q1 2026.
CG Oncology made up 0.43% of Sicart Associates's portfolio in Q1 2026, its #42 holding.
Sicart Associates first reported a position in CG Oncology in Q1 2024 and has held it in 9 quarters since.
233 funds tracked by Wall St. Rank held CG Oncology as of Q1 2026.

Based on Sicart Associates's 13F filing for Q1 2026, filed 21 Apr 2026.